1. Home
  2. LCTX vs FSP Comparison

LCTX vs FSP Comparison

Compare LCTX & FSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.57

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.60

Market Cap

64.7M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
FSP
Founded
1990
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
64.7M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
LCTX
FSP
Price
$1.57
$0.60
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
1.0M
585.8K
Earning Date
06-05-2026
01-01-0001
Dividend Yield
N/A
6.67%
EPS Growth
N/A
15.69
EPS
N/A
N/A
Revenue
$14,556,000.00
$107,162,000.00
Revenue This Year
$55.75
$17.91
Revenue Next Year
$2.96
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.24
N/A
52 Week Low
$0.37
$0.59
52 Week High
$2.09
$1.93

Technical Indicators

Market Signals
Indicator
LCTX
FSP
Relative Strength Index (RSI) 37.29 33.22
Support Level $1.55 N/A
Resistance Level $1.84 $0.89
Average True Range (ATR) 0.11 0.06
MACD -0.04 -0.01
Stochastic Oscillator 5.88 3.55

Price Performance

Historical Comparison
LCTX
FSP

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.

Share on Social Networks: